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Abstract
Introduction: In liver stereotactic body radiotherapy, reduction of normal tissue irradiation
requires daily image guidance. This is typically accomplished by imaging a surrogate to the tumor.
The surrogate is often an implanted metal fiducial marker. There are few reports addressing the
specific risks of hepatic fiducial marker implantation. These risks are assumed to be similar to
percutaneous liver biopsies which are associated with a 1-4% complication rate - almost always pain
or bleeding. To the best of our knowledge, we present the first case of such a fiducial marker
migrating to the heart.
Case presentation: An 81-year-old Caucasian man (5 years post-gastrectomy for a gastric
adenocarcinoma) was referred post-second line palliative chemotherapy for radiotherapy of an
isolated liver metastasis. It was decided to proceed with treatment and platinum fiducials were
chosen for radiation targeting. Under local anesthesia, three Nester embolization coils (Cook
Medical Inc., Bloomington, IN, USA) were implanted under computed tomography guidance.
Before the placement of each coil, the location of the tip of the delivery needle was confirmed by
computed tomography imaging. During the procedure, the third coil unexpectedly migrated
through the hepatic vein to the inferior vena cava and lodged at the junction of the vena cava and
the right atrium. The patient remained asymptomatic. He was immediately referred to angiography
for extraction of the coil. Using fluoroscopic guidance, an EN Snare Retrieval System (Hatch
Medical L.L.C., Snellville, GA, USA) was introduced through a jugular catheter; it successfully
grasped the coil and the coil was removed. The patient was kept overnight for observation and no
immediate or delayed complications were encountered due to the migration or retrieval of the coil.
He subsequently went on to be treated using the remaining fiducials.
Conclusion: Implanted fiducial markers are increasingly used for stereotactic radiotherapy. There
is sparse literature on the risks of such procedures. Although uncommon, the risk of migration
does exist and therefore physicians (surgeons, oncologists and radiologists) and patients should be
aware of this possibility.
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Introduction
Stereotactic body radiation therapy (SBRT) is a technique
that utilizes precise targeting of tumor irradiation in order
to minimize exposure of adjacent normal tissue [1]. SBRT
is used to treat a variety of primary and metastatic tumors
of the lung, liver, pancreas, kidney, spine and prostate [2].
In the use of SBRT for liver lesions, tumor-targeting accu-
racy is crucial given the radiosensitive nature of the liver,
frequent proximity of the target to the small bowel as well
as significant displacement of the liver with breathing.
In hepatic SBRT, reduction of normal tissue irradiation
requires image guidance [1]. This is typically accom-
plished through daily imaging of a surrogate to the tumor.
The surrogate can be the whole liver, the diaphragm or an
implanted marker. The imaging modality can be stereo-
scopic fluoroscopy, pretreatment megavoltage or kilovolt-
age imaging, cone-beam computed tomography (CT) or
'CT on rails'. Depending on the combination used,
implanted fiducials may or may not play a role. Although
non-fiducial-based strategies avoid an invasive procedure,
they do not typically permit imaging during treatment or
'tracking' of the tumor. At our center, we have used pre-
treatment megavoltage images of implanted fiducials for
targeting and continuous portal imaging during treatment
for quality assurance. While flexible helical gold coils are
commonly used [3] as fiducials, our access to such prod-
ucts had been limited by the lack of local regulatory
approval. We have found that platinum embolization
coils can be a safe and effective alternative for tumor local-
ization in stereotactic liver radiotherapy [4]. These coils
are easily inserted percutaneously with a small caliber
needle during a well-tolerated outpatient procedure.
Percutaneous fiducial implantation is minimally invasive
but does have risks and limitations [5]. The most com-
monly described complications involve implantation of
fiducials for lung SBRT. When pulmonary fiducials are
placed percutaneously, pneumothoraces are common,
while pulmonary hemorrhage is rare. There are limited
data specific to hepatic implantation. In a series of 21
patients implanted with 2 mm gold spheres, one of the
fiducials migrated through the inferior vena cava to a
small vein at the hip where it remained lodged without
apparent clinical consequence [6]. In a series from Stan-
ford University Medical Center, 33 patients underwent
CT-guided placement of 0.8 mmx5 mm hepatic fiducials.
In these cases, there was no gross marker migration and
one patient experienced a small hemorrhagic pleural effu-
sion [7]. Comparison with the liver biopsy literature may
provide a benchmark to estimate the risk of hepatic fidu-
cial implantation, as the techniques are similar. In the
extensive experience of percutaneous liver biopsies, the
reported risk of complications is 1 to 4% [8]. Serious com-
plications are almost always pain or bleeding (or sequelae
thereof).
Fiducial migration is a twofold issue, first of tumor mistar-
geting as a consequence of fiducial migration within the
targeted organ and second of potential direct toxicity from
the marker exiting the targeted organ.
Migration of fiducials within the targeted organ has been
described. Most published work concerns prostate radio-
therapy with studies looking at the relative position of
three to four prostate markers as a surrogate to migration
[9]. In limited experience with hepatic fiducials, intra-
organ migration appears minimal -- in the order of 2 to 3
mm [6,9]. However, quantification of movement within
the liver is limited by the frequent lack of precise land-
marks within this large, deformable organ. To deal with
this issue, clinicians have relied on treatment margins,
repeated three-dimensional imaging and/or implantation
of redundant fiducials.
Migration of seeds placed in the prostate for radiotherapy
is common. Most commonly, these prostate seeds do not
migrate acutely and are found in the lung on follow-up
imaging [10]. They can also migrate in the pelvis or abdo-
men as well as being expressed through the urethra. These
incidents are generally without complication although an
acute cardiac event due to migration into a coronary artery
has been described [11]. In the chest, benign migration of
fiducials can be seen into the airway or pleural space. To
the best of our knowledge, we report the second case of
extra-hepatic migration of a liver fiducial but the first case
where an implanted hepatic fiducial marker for SBRT tar-
geting embolized to the chest.
Case presentation
An 81-year-old Caucasian man had been diagnosed 5
years earlier with a gastric adenocarcinoma for which he
underwent surgery. At the time, adjuvant radiotherapy
was considered but was deferred when a liver metastasis
was discovered. The patient was treated with palliative
chemotherapy. He had an excellent treatment response
and was subsequently followed without treatment for 2
years before undergoing radiofrequency ablation for pro-
gression of his hepatic lesion. After four cycles of second
line palliative chemotherapy, the patient, still in excellent
general condition, was referred for SBRT as consolidation
treatment of what remained a metabolically active iso-
lated liver metastasis. It was decided to proceed with treat-
ment and platinum fiducials were chosen for SBRT
targeting. Under local anesthesia, Nester embolization
coils (Cook Medical Inc., Bloomington, IN, USA) were
implanted using a 21-gauge needle under CT guidance.
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an approximate configuration of 11.7 loops creating an in
vivo embolus of 4 mm.
For our patient, three coils were placed by an experienced
interventional radiologist: the first on the anterior and
medial border of the lesion, the second on the anterior lat-
eral border and the third on the posterior border of the
lesion. Before the placement of each coil, the location of
the tip of the delivery needle was confirmed by CT imag-
ing. On the immediate post-deployment CT, the third coil
was not seen in the liver. A scout CT image localized it in
the chest. During the procedure, the coil had unexpectedly
migrated through the hepatic vein to the inferior vena
cava (IVC) and lodged at the junction of the IVC and the
right atrium. The patient was asymptomatic but was
immediately referred to angiography for extraction of the
coil.
Using ultrasound guidance and accessing through the
right internal jugular vein, a guide wire was inserted over
which a straight multi-side hole catheter was inserted and
an angiogram was performed with the catheter tip within
the right atrium (Figure 1).
Using fluoroscopic guidance, an EN Snare Retrieval Sys-
tem (Hatch Medical L.L.C., Snellville, GA, USA) was used.
The tip of the catheter was slightly curved and inserted
over the guide wire toward the coil within the right
atrium. The EN Snare was introduced through the cathe-
ter; it successfully grasped the coil, and the coil was
removed through the sheath (Figure 2). The patient was
kept overnight for observation and no immediate or
delayed complications were encountered due to the
migration or retrieval of the coil.
Shortly after, it was possible to proceed with SBRT with
daily image guidance based on the previously implanted
platinum fiducials. Unfortunately, a short time thereafter,
the patient developed intra-hepatic bile duct dilatation.
This occurred secondary to documented tumor progres-
sion and was unrelated to the fiducial placement. The
patient underwent percutaneous biliary drainage and was
admitted to hospital for end of life care.
Discussion
Implanted markers have been shown to improve radio-
therapeutic precision and provide a target for tumor track-
ing. Although SBRT can be performed without fiducials,
these are mandatory for specific radiosurgery systems
[12]. Previous groups have principally used gold seeds as
fiducial markers [6,7]. We have reported our initial expe-
rience using platinum embolization coils as markers for
hepatic SBRT localization [4]. Platinum has an electron
density similar to that of gold and, in our experience, plat-
inum coils are a reasonable alternative to gold seeds or
baguettes. Moreover, platinum coil insertion has generally
been well tolerated by our patients with post-implanta-
tion transient hepatalgia as the only complication in 20 to
25% of patients.
The platinum coils have inherent thrombogenic proper-
ties through their embedded synthetic fibers, which may
help to minimize the risk of bleeding post-insertion. They
Digital subtraction angiogram with the catheter trip within  the right atrium Figure 1
Digital subtraction angiogram with the catheter trip 
within the right atrium. Arrows depict fiducial coil mark-
ers.
EN Snare retrieving coil from the right atrium (a) and passing  through the superior vena cava, (b) under fluoroscopic guid- ance Figure 2
EN Snare retrieving coil from the right atrium (a) 
and passing through the superior vena cava, (b) 
under fluoroscopic guidance.Journal of Medical Case Reports 2009, 3:140 http://www.jmedicalcasereports.com/content/3/1/140
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are inserted with a small caliber (21G), minimally trau-
matic needle thus enabling the procedure to be carried out
on an outpatient basis. Gold fiducials for megavoltage
imaging can require a biopsy caliber needle for insertion.
Thinner gold fiducials can be used if kilovoltage imaging
is available, although these smaller markers may be more
prone to migration. Given the coiled configuration, plati-
num embolization coils are thin enough to require a
small caliber needle for insertion and yet large enough to
create a readily visible 4 mm radiodense target. By its
nature and spiral configuration, migration of this marker
was thought to be unlikely. However, in this case report,
we have shown that migration is a possible complication.
The third coil implanted in this patient's liver migrated
through the hepatic vein to the IVC where it lodged at the
junction of the IVC and the right atrium and subsequently
had to be removed via catheterization. Fortunately, the
marker did not reach the pulmonary vasculature where it
may have caused a significant infarct.
For migration to occur, we believe that the needle tip
would have to have been inserted into a hepatic vein
branch with a diameter of several millimeters. In a vein of
this caliber, there is typically blood return when the nee-
dle stylet is withdrawn. In our patient, there was no blood
return. This leads us to postulate that the needle tip was in
parenchyma very close to an appropriately sized vein and
either the needle migrated or the act of deploying the
marker led to perforation of the vein wall. With deploy-
ment, the coil likely ended in an intravascular location
and was carried to the IVC by normal venous flow, high-
lighting the importance of immediate post-deployment
imaging.
In our patient, a risk factor for migration was the proxim-
ity of the tumor to a major hepatic vein. In such cases, the
risk may be mitigated by determining the location of
regional veins on pre-implantation contrast-enhanced
images and planning a safe approach. We now routinely
use intravenous contrast for all marker placements in the
superior portion of the liver, especially if in close proxim-
ity to a hepatic vein. Placement under ultrasound guid-
ance is an alternative, although we find it convenient to
have the possibility, in a single procedure, of acquiring a
contrast CT unencumbered by artifact immediately before
fiducial placement for use in treatment planning.
In stereotactic radiotherapy of pulmonary tumors,
endovascular fiducial placement has been used as a means
of reducing the risk of a pneumothorax [13]. In the liver,
the additional risks and inconveniences of formal angiog-
raphy would appear out of proportion to the small risk of
migration.
Conclusion
Interventional radiologists and radiation oncologists
often collaborate in the implantation of radio-opaque
markers for the targeting of focused radiation. There is
sparse literature on the risks of such procedures. Although
we have found the use of platinum embolization coils to
be a generally safe and effective option for tumor localiza-
tion in SBRT, complications may occur. To the best of our
knowledge, we report the first case of cardiac migration of
an implanted hepatic radiotherapy fiducial marker.
Although unlikely, the risk of migration does exist and
physicians and patients should be aware of this risk.
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